Table II.

Correlation between human cervical cancer clinicopathological features with LAIR-1 expression in subcellular localization.

	Cytoplasmic LAIR-1				Nuclear LAIR-1
Variable	− (n=15)	+ (n=54)	++ (n=55)	P-value	− (n=61)	+ (n=49)	++ (n=14)	P-value
Age				0.756				0.780
≤45	9 (12.9)	32 (45.7)	29 (41.4)		33 (47.1)	28 (40.0)	9 (12.9)
>45	6 (11.1)	22 (40.7)	26 (48.1)		28 (51.9)	21 (38.9)	5 (9.3)
Tumor size, cm				0.751				0.047
≤4	12 (13.5)	38 (42.7)	39 (43.8)		38 (42.7)	41 (46.1)	10 (11.2)
>4	3 (8.6)	16 (45.7)	16 (45.7)		23 (65.7)	8 (22.9)	4 (11.4)
Pathological stage				0.390				0.014
G1	0 (0.0)	3 (42.9)	4 (57.1)		1 (14.3)	3 (42.9)	3 (42.9)
G2	9 (9.4)	43 (44.8)	44 (45.8)		45 (46.9)	43 (44.8)	8 (8.3)
G3	4 (23.5)	7 (41.2)	6 (35.3)		11 (64.7)	3 (17.6)	3 (17.6)
Number of positive lymph nodes				<0.001				0.492
0	9 (10.7)	37 (44.0)	38 (45.2)		45 (53.6)	32 (38.1)	7 (8.3)
≤3	0 (0.0)	7 (36.8)	12 (63.2)		9 (47.4)	7 (36.8)	3 (15.8)
>3	5 (41.7)	3 (25.0)	4 (33.3)		5 (41.7)	4 (33.3)	3 (25.0)
T classification				0.090				<0.001
T1	12 (15.0)	37 (46.3)	31 (38.8)		39 (48.8)	37 (46.3)	4 (5.0)
T2	3 (8.8)	14 (41.2)	17 (50.0)		21 (61.8)	9 (26.5)	4 (11.8)
T3	0 (0.0)	0 (0.0)	5 (100.0)		0 (0.0)	2 (40.0)	3 (60.0)
N classification				0.746				0.251
N0	9 (10.8)	37 (44.6)	37 (44.6)		45 (54.2)	32 (38.6)	6 (7.2)
N1	6 (15.8)	16 (42.1)	16 (42.1)		16 (42.1)	16 (42.1)	6 (15.8)
Clinical stage				0.914				0.027
1	6 (12.8)	22 (46.8)	19 (40.4)		24 (51.1)	22 (46.8)	1 (2.1)
2	3 (9.7)	13 (41.9)	15 (48.4)		20 (64.5)	8 (25.8)	3 (9.7)
3	6 (14.6)	16 (39.0)	19 (46.3)		16 (39.0)	17 (41.5)	8 (19.5)

LAIR-1, leukocyte-associated immunoglobulin-like receptor-1; -, immunoreactive score (IRS) 0; +, IRS 1–4; ++, IRS 6–12.